We consider nucleation of amyloid fibrils in the case when the process occurs by the mechanism of direct polymerization of practically fully extended protein segments, i.e. -strands, into -sheets. Applying the classical nucleation theory, we derive a general expression for the work to form a nanosized amyloid fibril (protofilament) constituted of successively layered -sheets. Analysis of this expression reveals that with increasing its size, the fibril transforms from one-dimensional into two-dimensional aggregate in order to preserve the equilibrium shape corresponding to minimal formation work. We determine the size of the fibril nucleus, the fibril nucleation work and the fibril nucleation rate as explicit functions of the concentration and temperature of the protein solution. The results obtained are applicable to homogeneous nucleation which occurs when the solution is sufficiently pure and/or strongly supersaturated.
I. INTRODUCTION
Understanding the nucleation mechanism by which proteins assemble into highly ordered structures known as amyloid fibrils is a much-studied problem because of its implications for human health and nanotechnology. At present there are about 25 different disorders categorized as amyloid diseases including Alzheimer's and Parkinson's disease, 1 and the application of peptide building blocks in bio-sensors, tissue engineering, and antibacterial agents has recently been demonstrated. 2 Structural studies 1, 3 have shown that amyloid fibrils formed by different proteins are composed of protofilaments that are wound together to form higher-order fibrillar structures. The protofilaments themselves are composed of several -sheet layers that share a common characteristic cross- structure. The application of electron and X-ray diffraction and of solid state NMR spectroscopy to microcrystals of various short peptide fragments and to amyloid fibrils also gives evidence of this structure. [4] [5] [6] [7] [8] It is now well established that fibrillar protein aggregates form through a nucleation mechanism. Their formation kinetics is characterized by an initial lag time during which no aggregates are detected and a maximal rate of the overall aggregation process. Timeresolved optical experiments that measure the fluorescence signal arising from dye molecules such as thioflavin-T bound to the protein aggregates enable determination of the lag time and the maximal aggregation rate. Interestingly, the product of these two quantities is nearly the same for a wide range of aggregation conditions and protein systems. 34, 35 So far, a considerable effort has been devoted to understanding how the amino acid sequence of proteins and the experimental conditions affect the kinetics of amyloid fibril formation. 30, 32, 33, [36] [37] [38] [39] [40] [41] [42] [43] [44] Experiments that investigate the physiochemical properties of the natural amino acids (such as -propensity, hydrophobicity, aromatic content and charge) have been used to substantiate phenomenological models able to predict changes in the aggregation rate upon mutation as well as to predict amino acid sequences of proteins, so-called hot spots, that are likely to belong to the fibril core. [45] [46] [47] [48] [49] [50] Although both the experimental studies and the theoretical models show that the kinetic parameters of aggregation depend strongly on the specificity of the amino acid sequence of the protein, it may be expected that this specificity is a particular expression of a common fibril nucleation/growth mechanism which could be treated in the framework of existing general theories of nucleation and growth of new phases.
Treating protein aggregation as a nucleation-mediated process is necessarily based on the concept that the process is reversible. This is so, because nucleation can only occur in a metastable protein solution, and the solution metastability can only be defined by means of the protein equilibrium (or saturation) concentration at which the bulk protein phase neither grows nor dissolves in the solution. Below this concentration (known also as solubility) the solution is undersaturated so that nucleation and growth are impossible, and existing protein aggregates dissolve. Both experiments (e.g., Refs. 18, 30, 44, [51] [52] [53] [54] and computer simulations (e.g., Refs. 31, 55) give evidence for the existence of equilibrium peptide concentration and for the dissolution of amyloid fibrils in sufficiently dilute solutions. Knowing the equilibrium concentration of monomeric peptide allows determination of the supersaturation for fibril nucleation, and the fibril dissolution demonstrates that fibril formation is not an irreversible process.
In this article, our objective is to apply the classical nucleation theory (CNT) (e.g.,
Refs. 56,57) and the recently proposed corrected CNT (CCNT) 58 for describing the nucleation of amyloid fibrils by the mechanism of direct polymerization of practically fully extended protein segments, i.e. -strands, into -sheets. This mechanism is operative under conditions when no fibril precursors such as droplet-like peptide aggregates appear in the solution as a first step in the fibril nucleation process. By assuming that the nanosized amyloid fibril (protofilament) is built up of successively layered -sheets, we derive a general expression for the work to form such a fibril. This expression is used for determination of the size of the fibril nucleus, the fibril nucleation work and the fibril nucleation rate. The results obtained are applicable to homogeneous nucleation which occurs when the protein solution is sufficiently pure and/or strongly supersaturated.
II. PHYSICAL MODEL
The model we propose is based on structural and morphological studies of amyloid fibrils and microcrystals, 4, 5, 7, 8, 52, 59 as well as on computer simulation results for amyloid fibril formation. [21] [22] [23] 31, 54 Our considerations thus pertain to nanosized amyloid fibrils (protofilaments) built up of successively layered -sheets with fixed width and thickness. and a h (m 2 ) of its two different side surfaces (Fig. 1) . These areas are given by
(m) is the intersheet distance in the fibril, and d 0 (m) is the extended peptide length, i.e. the -sheet width.
Since the fibril is with fixed width equal to that of the constituting -sheets, it can be conceived as a two-dimensional (2D) phase in the m,i plane. The fibril is thus congenial with a 2D rectangularly shaped crystallite and its nucleation, lengthening along the m axis and thickening along the i axis could be described in the scope of existing crystal nucleation and growth theories (e.g., Refs. 56,57). Important parameters in these theories are the specific surface energies of the different crystal faces. For the fibril in Fig. 1 , we denote by  (Jm   2 ) and  h (Jm 2 ) the specific surface energies of the faces perpendicular to the m axis and the i axis, respectively. The third fibril specific surface energy,  0 (Jm 2 ), is that of the fibril face in the m,i plane. However, knowing this energy is not necessary for the present considerations, because they are restricted to the earliest stage of fibril formation when the fibrils are so small that they change their size solely along the m and i axes. As they are then 2D formations,  0 participates only implicitly, via the supersaturation  (J), in the description of their nucleation (see Section III).
By definition, the specific surface energy is equal to the work done on creating a unit area of the respective face by cutting the fibril along a plane parallel to the face and separating the resulting two half-fibrils far enough from each other. For that reason, the  and  h values are largely determined by the strength of the interpeptide bonds within the fibril. Whereas along the m axis the peptide bonding is dominated by the hydrogen bonds, 60 along the i axis the peptides (and, hence, the -sheets) are bound by much weaker bonds such as those due to the hydrophobic effect. Therefore, since to a first approximation the surface energy is proportional to the bond energy, the amyloid fibrils are characterized by the times lower than the hydrogen bond energy between nearest-neighbor peptides in a -sheet.
III. WORK OF FIBRIL FORMATION
At a given absolute temperature T (K) of the solution there exists a concentration C e (m 3 ) of peptide monomers, called the equilibrium concentration or solubility, at which a macroscopically large fibril neither grows nor dissolves. The solution is then saturated and fibril nucleation is impossible. When the actual concentration C 1 (m 3 ) of peptide monomers in the solution is lower or higher than C e , the solution is undersaturated or supersaturated, respectively. While in the former case the system is in a thermodynamically stable state and fibril nucleation is again impossible, in the latter case the system is metastable and already able to nucleate fibrils that can grow up to macroscopic sizes. Using the physical model described above, we shall now determine the work W i,m (J) to form a nanosized amyloid fibril of thickness i, length m and size im n  (n is the number of peptides constituting the fibril).
From nucleation theory (e.g., Refs. 56,57), the general expression for W i,m is of the form
where  s (J) and  f (J) are, respectively, the chemical potentials of a peptide in the solution and in the bulk fibrillar phase of which the fibril is the precursor, and 
Importantly, CNT neglects the possible dependence of  0 ,  and  h on the fibril size. We note also that unlike the rigid crystallite, the fibril is a flexible formation which is why Combining Eqs. (1) and (2), we obtain
where the supersaturation 0   , defined by
is the driving force for nucleation of 2D fibrils and their further growth in length and thickness, i.e. along the m and i axes. From Eq. (3) we thus find that the dimensionless work
to form an i,m-sized fibril is given by 
for solutions in which the supersaturation is experimentally controlled by C 1 at a given T or by T at a given and from Eq. (5) we find that the formation of 1-sheet of n peptides, i.e. of a single n-sized -sheet, requires the work
The straight lines 1 in Fig. 2 
the work w 1,n from Eq. (6) does not change with the 1-sheet size n. Physically, this means that at s 1 the 1-sheet is in thermodynamic equilibrium (or coexistence) with the solution.
According to Eq. (7), s 1 scales with the fibril "hydrophobic" specific surface energy  h . What is important about the 1-sheet is that it cannot grow unlimitedly as onedimensional (1D) formation, i.e. in length only. This is so, because when the 1-sheet is constituted of too many peptides, its total surface energy may already be higher than that of a 2-sheet of the same size n. As at fixed n the fibril total surface energy has to be minimal, the most probable fibril shape will be the one that satisfies this thermodynamic requirement. This so-called equilibrium fibril shape is characterized by that value of the im ratio which fulfils 
so that, upon eliminating i and m from Eq. (5) with the help of these relations, we obtain
This equation is of the form known from the classical theory of 2D nucleation (e.g., Ref. 56).
Importantly, Eq. (10) is not valid for fibrils containing
peptides and having the equilibrium shape, because according to Eq. (9) such small fibrils would be with the physically meaningless thickness of 1  i . This leads inescapably to the conclusion that the fibrils commence their ontogenesis as single -sheets, i.e. as 1D aggregates, and continue it as 2D formations with equilibrium shape only after reaching the supersaturation-independent transition size n t given by
For instance, fibrils characterized with ) and by Eq. (10) when the fibril size is large enough ( t n n  ). Figure 2 reveals also that at any t n n  the work w n from Eq. (10) is smaller not only than the work w 1,n from Eq. (6), but also than the work
to form an i-sheet of the same number n of peptides and any given number ,...
sheets. Equation (12) Figure 2 shows also that at a certain s value the work w 2,n does not change with n (the uppermost line 2 has no slope). This means that at this supersaturation no work is done on attaching or detaching peptides to or from a 2-sheet. Hence, regarded as a distinct peptide phase, the 2-sheet is then in equilibrium or coexistence with the solution. Similarly, if conceived as different peptide phases, the 3-, 4-, etc. sheets can coexist with the solution, but at different supersaturations which we shall denote by s i . These coexistence supersaturations are readily obtained by setting equal to zero the bracketed factor in Eq. (12) , because this factor is the driving force for i-sheet growth or dissolution. Doing that leads to the formula ( ,... (13), we find that the equilibrium concentration C i of peptide monomers and the equilibrium temperature T i at which the i-sheet neither grows nor dissolves at a given T or C 1 , respectively, are of the form ( ,...
These expressions say that while C i decreases, T i increases with increasing the i-sheet thickness i. This behavior of C i and T i is in agreement with that seen in a peptide phase diagram obtained by kinetic Monte Carlo simulations of aggregation of -sheet forming peptides in solution. 55 In the limit of   i , i.e. when the i-sheet is sufficiently thick, C i and T i are equal to the equilibrium concentration C e of peptide monomers and the equilibrium temperature T e that characterize the macroscopically large fibrillar phase.
IV. NUCLEUS SIZE AND NUCLEATION WORK
Curve 1 in Fig. 2 depicts the change of w n with n when fibril formation is nucleationmediated and the fibrils have their equilibrium shape. It is seen that then w n passes through a maximum (marked by the star on curve 1) at a given fibril size n*. Thus, among the fibrils of different size, the n*-sized fibril is distinguishable with the greatest formation work. The fibril constituted of n* peptides is the so-called nucleus (or critical nucleus), and the work 
The dashed lines in Fig. 3 Fig. 2 ) and, also, Eq. (18) yields the physically irrelevant result 1 *  i .
Thus, at the highest supersaturation s 1 at which CNT is applicable, the CNT nucleus is a single -sheet, n t peptides in length, formed without any work for the attachment of 1  t n peptides to the initial single peptide (see the middle line 1 in Fig. 2 ).
All of the above considerations are in the scope of CNT which provides a clear and mathematically simple description of the nucleation energetics. Recently, however, it has been shown 58 that this theory may underestimate considerably the nucleation work of crystals and, as a consequence, overestimate by many orders of magnitude the crystal nucleation rate.
In the case of 2D nucleation, the reason for this grave inaccuracy is that CNT disregards the work W a (J) done on attaching the first molecule to the periphery of the crystal nucleus. This molecule triggers the propagation of a molecular row along the nucleus periphery and, thereby, the growth of the nucleus itself. We shall now apply CCNT 58 in order to quantitatively improve the CNT Eqs. (16) and (17) for the fibril nucleus size and nucleation work. As to the CNT Eq. (10) for w n , CCNT does not provide a correction for it. Figure 4 illustrates the CNT and CCNT fibril nuclei at one and the same supersaturation. The CNT nucleus (Fig. 4a) can preserve its equilibrium shape solely by growing in both thickness and length. However, as discussed also by Zhang and Muthukumar, 31 thickening is what actually impedes its growth because of the weak binding of the peptides to the surface of the nucleus outer -sheets, i.e. to the nucleus  h -faces. The CNT nucleus needs just one more peptide (shown shaded in Fig. 4b ) on one of these faces in order to be able to acquire barrierlessly the rest of the peptides necessary for the nucleus thickening by building-up of a new -sheet. Indeed, while on attaching one peptide to the nucleus  h -face the work skT      is gained because of the peptide becoming part of the thermodynamically stable fibrillar phase, the work kT a
is spent due to the augmenting of the nucleus total surface area by the area 2a of the peptide two -faces (as seen in Fig. 4 , in this process the peptide two  h -faces do not contribute to the increase in the nucleus total surface area). Hence, the dimensionless overall peptide attachment work
Subsequent attachment of a peptide to one of the -faces of the already attached first peptide does not change the nucleus total surface area so that in this process work is only gained, the gain being again   
. Similarly, further successive lateral attachment of peptides is thermodynamically favored, because it requires no work to be done until the complete building-up of a whole new -sheet on the CNT nucleus.
It follows from the above that the CCNT fibril nucleus (Fig. 4b) is one peptide bigger than the CNT one (Fig. 4a) and that the CCNT nucleation work equals the CNT one plus the work for the first peptide attachment to a -sheet surface. Thus, in view of Eqs. (16), (17) and (20) Also, it is seen that they are related by the simple formula
The CCNT n*(s) and w*(s) dependences predicted by Eqs. (21) and (22) are represented in Fig. 3 by the solid lines n* and w*, respectively. We observe that while the CCNT correction has practically no effect on the CNT nucleus size, it affects strongly the CNT nucleation work. Importantly, while at However, at these high supersaturations fibril nucleation is non-classical, because considerations beyond the CNT requirement for equilibrium fibril shape are necessary for determination of the corresponding nucleation barrier and of the limiting supersaturation at which this barrier vanishes and above which fibril formation occurs barrierlessly, i.e. in the so-called metanucleation regime.
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V. NUCLEATION RATE
In nucleation of fibrils in the volume of a supersaturated solution the nucleation rate J (m 3 s 1 ) is the frequency of appearance of supernucleus fibrils per unit solution volume.
According to the classical Szilard-Farkas model of nucleation (e.g., Refs. 56,57), random attachment and detachment of single peptides, i.e. peptide monomers, to and from a subnucleus fibril is the mechanism by which this fibril may eventually grow bigger than the nucleus and become a supernucleus. This mechanism of direct polymerization leads to a simple expression for the nucleation rate when the solution supersaturation and temperature are kept constant. Then nucleation occurs in stationary regime and its time-independent or stationary rate J is given by the general formula (e.g., Refs. 56,57) 
where w 1,1 is the dimensionless work for monomer formation (the monomer is formally considered as the smallest representative of the nucleating phase). Equation (25) We can now obtain the CNT formula for the stationary rate J of fibril nucleation.
Substituting z, C* and f* from Eqs. (24) - (26) 
Using this equation should however be avoided, because it has been shown 58 that it is highly inaccurate for crystals with dimensionless specific surface energy 1   . The quantitatively reliable formula for J is the CCNT one and, to find it, we use again Eq. (23) with C* from Eq. (25), but with w* from the CCNT Eq. (22) . In addition, we employ the
, because only half of the equilibrium nucleus concentration C* is effective in stationary nucleation 56 and because after attaching a peptide, the CCNT nucleus virtually always grows to a macroscopically large size. Also, in accordance with Eq. (26), we approximate * f by
, since in most cases the CCNT nucleus is expected to be two -sheets thick (one -sheet plus one peptide on the sheet). Thus, with the aid of these approximations for z and f* and of the above expression for w 1,1 , we obtain the CCNT J(s)
Comparing J from Eqs. (27) and (28), we see that the CCNT nucleation rate is much lower that the CNT one, because the exponential function in Eq. (28) (28) 
where the C 
This important formula shows that when available isothermal J(C 1 ) data are plotted in J lnvs.-1 lnC coordinates, the slope of the resulting line is a direct measure of the nucleus size. Equation (32) parallels that in Ref. 13 and, as can be readily verified, it holds true also for the CNT n* and J from Eqs. (16) and (27) . This is so, because Eq. (32) In the other case of experimental interest, the case when s is controlled with the aid of T at fixed C 1 , the proportionality of
can be expressed as
, where the virtually T-independent frequency factor f 0 (s 1 ) is
Here the kinetic factor A (m 3 s 1 ), the thermodynamic parameter B (K 2 ) and the effective activation energy E (J) are specified by
and it should be kept in mind that Eq. (33) is applicable provided the peptides remain in extended conformation in the entire temperature range studied (then all three parameters A, B
and E in the equation can be treated as practically T-independent).
Equations (28), (29) and (33) are also a central result of the present study. The concentration dependence of J from Eq. (29) is illustrated in Fig. 5 As seen from (16). We observe that at the exemplified values of  and  h the CNT nucleation rate is about 11 orders of magnitude higher than the CCNT one. This spectacular overestimation is almost entirely due to the CNT underestimation of the nucleation work w* (see Fig. 3 ), because the pre-exponential factors in Eqs. (27) and (28) 
VI. CONCLUSION
The analysis made shows that application of existing general theories of nucleation of new phases to amyloid fibril nucleation by the mechanism of direct polymerization can supply valuable information about both the thermodynamics and the kinetics of the process.
The modeling of the nanosized amyloid fibrils (protofilaments) by prismatic aggregates with fixed width, changing thickness determined by the number of successively layered -sheets in them, and changing length equal to the number of peptides in a -sheet leads to the general CNT formula, Eq. (5), for the work to form a fibril of given size. This work is expressed by Eq. (12) when the fibril evolves with constant number of constituent -sheets and by Eq. (10) when it preserves equilibrium shape during its evolution. Due to the impossibility of the smallest fibrils to be less than one -sheet thick, a fibril first develops as an 1D aggregate and becomes a 2D one only later, after reaching the transition size n t given by Eq. (11) . Both the transition size and the equilibrium shape of the bigger fibrils are controlled by the ratio of the specific surface energies  and  h of the fibril faces normal to the fibril elongation and thickening axes. These energies affect also the fibril nucleus size n* and nucleation work w* whose CNT dependences on the supersaturation s are given by Eqs. (16) and (17) . The corresponding CCNT dependences are given by Eqs. (21) and (22) and have always to be used for a more accurate determination of n* and, especially, of w*. Importantly, CCNT predicts that fibril formation remains nucleation-mediated at supersaturations even higher than the supersaturation s 1 at which the CNT nucleation barrier vanishes. At these high supersaturations, however, fibril nucleation is non-classical, because the respective nucleation barrier cannot be determined with the help of the CNT requirement for equilibrium shape. Equations (21) and (22) show that changes in  and/or h brought about, e.g., by alteration of the solution ionic strength, adsorption of impurity molecules on the fibril faces or mutations along the peptide chain may cause significant changes in n* and w* and, thereby, in the fibril nucleation kinetics.
The kinetics of stationary fibril nucleation is characterized by the nucleation rate J which is determined much more accurately by CCNT than by CNT because of the adequate Currently, open questions in nucleation of amyloid fibrils are, e.g., the surface energies and the equilibrium shape of the fibrils, the size of the nucleus fibril, the magnitude of the nucleation barrier, the mechanism of peptide attachment to the fibrils and, most importantly, the dependence of the nucleation rate on the peptide concentration and solution temperature. The analysis made offers answers to some of these questions and the results obtained in the paper could be a helpful guide in studying the intriguing phenomenon of amyloid fibril nucleation.
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APPENDIX A: THE SUPERSATURATION
In experiments on protein aggregation, the supersaturation  is usually controlled either by the concentration of monomer protein at a fixed solution temperature (e.g., Refs. [9] [10] [11] [12] [13] [14] [16] [17] [18] 29, 30, 33, 36, 38, 44, [52] [53] [54] 68, 70) or by the temperature at a fixed protein concentration (e.g., Refs. 9, 10, 14, 19, 25, 26, 70, 74, 76) .
To express  from Eq. (4) in terms of the concentration C 1 of monomer peptide at a fixed temperature T we recall that when the solution is sufficiently dilute, thermodynamically,  s and C 1 are related by (e.g., Refs. 56,57)
Hence,  from Eq. (4) becomes
The C , we obtain the known (C 1 ) formula for nucleation of condensed phases in solutions (e.g., Refs. 56,57)
We note, however, that for more concentrated peptide solutions a more accurate evaluation of  requires replacing the concentrations in Eq. (A4) by the corresponding activities. 56, 57 Also, in some cases the neglected term )] ( ) ( 
in which Being expressed via quantities that refer to the equilibrium between two bulk phases, the solution and the macroscopically large fibrillar phase, the latent heat L of fibril formation is a well-defined parameter independent of the fibril length and/or thickness. In both real and computer experiments L can be determined by plotting solubility-vs-temperature data in lnC e -vs-(1/T) coordinates. 31, 54, 55 If L is T-independent, the resulting line is straight, and the L value is obtainable from the slope of this line. Experiments on peptide solubility 54 
